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ABSTRACT
Retinoids are morphogens and have been implicated in cell fate commitment of embryonic
stem cells (ESCs) to neurons. Their effects are mediated by RAR and RXR nuclear receptors.
However, transcriptional cofactors required for cell and gene-specific retinoid signaling are not
known. Here we show that protein arginine methyl transferase (PRMT) 1 and 8 have key roles
in determining retinoid regulated gene expression and cellular specification in a multistage neu-
ronal differentiation model of murine ESCs. PRMT1 acts as a selective modulator, providing the
cells with a mechanism to reduce the potency of retinoid signals on regulatory “hotspots.”
PRMT8 is a retinoid receptor target gene itself and acts as a cell type specific transcriptional
coactivator of retinoid signaling at later stages of differentiation. Lack of either of them leads to
reduced nuclear arginine methylation, dysregulated neuronal gene expression, and altered neu-
ronal activity. Importantly, depletion of PRMT8 results in altered expression of a distinct set of
genes, including markers of gliomagenesis. PRMT8 is almost entirely absent in human glioblas-
toma tissues. We propose that PRMT1 and PRMT8 serve as a rheostat of retinoid signaling to
determine neuronal cell specification in a context-dependent manner and might also be rele-
vant in the development of human brain malignancy. STEM CELLS 2015;33:726–741
INTRODUCTION
Animal cells in developing embryos receive
positional signals from diffusible molecules,
called morphogens. Retinoic acid (RA), a natural
metabolite of vitamin A, has been proposed to
be a vertebrate morphogen [1, 2]. Molecularly,
RA acts via the activation of Retinoic Acid
Receptor : Retinoid X Receptor (RAR:RXR) heter-
odimers. RARs and RXRs are two subfamilies of
nuclear receptors (NRs) that bind to DNA motifs
called RA-response elements (RAREs), typically
arranged as direct repeats (DR) and regulate
transcription [3]. Unliganded RAR:RXR hetero-
dimers bind to corepressor complexes and are
thought to maintain target genes in a repressed
state [4]. Ligand binding stimulates a cascade of
events resulting in the release of the corepres-
sor complexes, recruitment of transcriptional
coactivators, and thus initiation of transcription
[5, 6]. However, the composition of coactivator
and corepressor complexes is cell-type and
context dependent and contributes to cell
specification and potentially gene-specific tran-
scription [7].
Members of the protein arginine methyl
transferase (PRMT) family have been shown to
act as nuclear receptor coactivators [8–11].
Based on their enzyme activity PRMTs are
grouped into three groups. Type I enzymes
(PRMT1, 2, 3, 4, 6, and 8) catalyze the forma-
tion of asymmetric dimethylarginine (aDMA)
residues while the type II (PRMT5) enzyme
catalyze the formation of symmetric dimethy-
larginine (sDMA) residues. Both type I and II
enzymes generate monomethylarginine (MMA)
intermediates. The type III enzyme (PRMT7)
only generates a MMA mark [12].
Importantly, asymmetric arginine methyla-
tion is associated with cellular differentiation
[13, 14]. Early studies revealed high level of
aDMA in the nervous system [15], however
expression profile of type I PRMTs and their
functional contribution to neurogenesis
remained largely uncharacterized [16–19].
PRMT1 is a major type of protein arginine
methyltransferase and the most studied one
[20]. Importantly, PRMT1 null mice die at an
early stage, indicating its essential role in em-
bryonic development [17]. PRMT1-dependent
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methylation of Arg3 on H4 tail peptides facilitates P300-
mediated histone H4 acetylation in vitro [21–23]. These studies
collectively suggest that PRMT1 is likely to collaborate with P300
to regulate transcription.
Mechanistically, PRMT1 dimerization/oligomerization or
heterodimerization may be required for PRMT1 to achieve its
coactivator function [24]. A comparison of mammalian PRMTs
revealed that PRMT8 is PRMT1’s closest paralog within this
enzyme family, with an identical exon structure and a brain
specific expression pattern and can form a heterodimer with
PRMT1 [25].
In this work, we explored the mechanistic and functional
role of PRMT1 and PRMT8 using a multistage differentiation
model of mouse embryonic stem cells (ESCs) to neurons. Our
findings implicate asymmetric arginine methylation as a novel
way to regulate the potency of retinoic acid regulated tran-
scriptional response. We show that PRMT1 and PRMT8 are
linked and act as part of a rheostat to integrate retinoid sig-
naling into neuronal specific gene expression governed by ret-
inoids with implications to neurological disorders.
MATERIALS AND METHODS
Additional details about all of the mehods listed below, infor-
mation about the antibodies used and related citations can
be found in the Supporting Information/Extended Experimen-
tal Procedures.
Mouse ESC Culture and Neural Differentiation
Wild type and genetically modified (see in the text) mouse
ESCs (mESCs) (kind gift of Tomo Saric and Istvan Szatmari)
were cultured on 0.1% gelatin-coated plates in feeder-free
condition in 5% CO2 at 37
C. Cells were differentiated through
embryoid body (EB) formation [26].
Ligands and Treatment
Cells were treated with vehicle (dimethylsulfoxide) or with
the following ligands: LG268 (a gift from R. Heyman; Ligand
Pharmaceuticals, San Diego, CA), RA (Sigma-Aldrich, St. Louis,
MO), or AM580 [27].
Gene Silencing Assays
Small hairpin RNA (shRNA) lentiviral plasmids (MISSION
shRNA, TRCN0000018490-493 and TRCN0000097479-482)
were purchased from Sigma (Sigma-Aldrich, St. Louis, MO) for
targeting the mouse PRMT1 and PRMT8, respectively.
Chromosome Counting
Cells were treated with colcemid (Sigma-Aldrich, St. Louis,
MO) for mitotic arrest and harvested by standard hypotonic
treatment and methanol: acetic acid (3:1) fixation. Slides were
prepared by standard air-drying method. Twenty DAPI (40, 6 -
Diamidino-2-phenylindole) stained chromosomal spreads were
counted in each case.
Teratoma Assay
mESCs were trypsinized and resuspended in 0.9% normal
saline at a concentration of 5 3 106 cells per ml. Severe com-
bined immunodeficiency (SCID) mice were anesthetized, and
100 ll of the cell suspension was injected into the lower leg.
After 4–6 weeks, the teratomas were surgically dissected,
fixed, embedded in paraffin, and sectioned. The sections were
then hematoxylin and eosin stained.
Real-Time Quantitative Reverse Transcriptase
Polymerase Chain Reaction
Total RNA was isolated with TRIZOL reagent (Invitrogen, Carlsbad,
CA, http://www.invitrogen.com). cDNA synthesis was performed
with High Capacity cDNA Reverse Trancription kit (Applied Biosys-
tems, Foster City, CA, http://www.appliedbiosystems.com)
according to the manufacturer’s recommendation. Quantitative
polymerase chain reaction (PCR) was performed using real-time
PCR (ABI PRISM 7900, Applied Biosystems). Gene expression was
quantified by the comparative CT method and normalized to
Gapdh. Values are expressed as mean6 SD of the mean. Graph-
Pad Prism version 5.02 was used for data interpretation. The
sequences of the primers and probes are available upon request.
Calcium Imaging, Loose-Patch and Whole-Cell Patch-
Clamp Recording
ESCs were differentiated to neurons for 16 days. Whole cell
patch clamp and calcium imaging experiments were conducted
on these cells to investigate their functional properties. For the
measurement of intracellular calcium concentration changes,
cells were and loaded with the calcium indicator dye Oregon
Green 488 BAPTA-1, AM. Calcium imaging measurements were
carried out as described by Koszeghy et al. [28] with minor
modifications. Patch clamp experiments were conducted simi-
larly as in Koszeghy et al. [28] with some alterations.
RNA-seq and Analysis
RNA-Seq library was prepared from two biological replicates
by using TruSeq RNA Sample Preparation Kit (Illumina) accord-
ing to manufacturer’s protocol. Illumina RNA-sequencing was
performed using standard procedures at the Centre National
de Genotypage (CNG) Paris, France.
The TopHat-Cufflinks-CummeRbund toolkit trio was used
for mapping spliced reads, making transcript assemblies, and
getting, sorting, and visualizing gene expression data. Series
accession number: SRP042072 / PRJNA248061.
Microarray Analysis
Data have been analyzed using GeneSpring v12.6. All microar-
ray data from this study have been submitted to the Gene
Expression Omnibus (Series accession number: GSE37060 and
GSE37060). Gene lists were imported into IPA (Ingenuity Sys-
tems, www.ingenuity.com) to carry out pathway analysis.
Enrichment of Histone Modification
Cells were washed and labeled with rabbit anti-H4R3me2a
primary antibody diluted 3800 in 1% Bovine Serum Albumin/
13Phosphate Buffer Saline/5 mM EDTA at 4C overnight
using a total volume of 150 ll labeling solution on each
slides. Data evaluation and hardware control were performed
by the iCys 3.4 software for Windows XP.
Chromatin Immunoprecipitation and Sequencing
Chromatin immunoprecipitation (ChIP)-qPCR and ChIP-seq
experiments were carried out as previously described [29],
with minor modifications. Primary analysis of the ChIP-seq
raw reads has been carried out using the ChIP-seq analyze
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command line pipeline. IGV (Integrative Genomics Viewer)
was used for data visualization. All ChIP-seq data from this
study have been submitted to the Sequence Read Archive,
NCBI (Series accession number: SRP042072/PRJNA248061).
Tissue Samples
Glioblastoma and normal brain tissues were collected during
neurosurgical operations in the Department of Neurosurgery,
University of Debrecen. Normal samples were collected either
during functional neurosurgery for epilepsy or nontumor her-
niated brain tissue during tumor surgery. Sections for histolog-
ical analysis were cut from the same samples used for mRNA
analysis. All procedures were approved by the National Ethical
Committee, and every patient signed an informed consent
form.
RESULTS
Asymmetric Arginine Methylation Is Present in Distinct
Stages of RA-Induced Neural Differentiation
To explore the involvment of arginine methylation in neuronal
development, we set up an ESC-based model system (Fig. 1A).
The four stages are: (I) undifferentiated ESCs, (II) aggregates
of spontaneously differentiating cells (termed EBs), (III) cells
commited to neuroectoderm as a result of all-trans RA treat-
ment, and (IV) the fully differentiated neuronal cells [26].
Importantly, these terminally differentiated neurons have elec-
trophysiological properties similar to those brain-derived neu-
rons and show positive staining for synapsin (Fig. 1B;
Supporting Information Fig. S1A), this is in line with the find-
ings of others on ESC derived neurons differentiated using the
same method [30].
This model system allows a systematic step-by-step analy-
sis of early cell fate commitment as well as late neural cell
type specification. As Supporting Information Figure S1B
shows, these stages can be characterized by distinct gene
expression signatures. Undifferentiated ESCs express high level
of stem cell specific Oct3/4 [31], while upon induction of
spontaneous differentiation the level of Oct3/4 is declining.
Treatment with RA causes the activation of RA signaling as it
is reflected by the increased Rarb expression. At this stage,
cells become Pax6-positive neural progenitor cells with the
characteristics of radial glial cells [26]. Members of the Hox-
family, such as Hoxb1, are also induced. In the last stage, high
expression of Tuj1 and Dcx, two well-established markers of
neurogenesis can be detected [32].
Using this multistage differentiation system, we have
found that proteins with sDMA and aDMA residues are pres-
ent in ESCs (Fig. 1C; Supporting Information Fig. S1C). Asym-
metric arginine methylation level of these proteins was
changing dynamically during RA-induced neural differentiation,
suggesting either an increased level of target proteins or over-
all type I enzyme activity. A 68-kDa protein (likely Sam68, a
previously identified arginine methyltransferase target) [33]
showed dramatically increased Asym24 level. Increased
expression of Sam68 during neural differentiation could be
also detected (Supporting Information Fig. S1C, S1D). Impor-
tantly, symmetric arginine methylation was not altered signifi-
cantly (Fig. 1C; Supporting Information Fig. S1C).
As the next step, we assessed the expression profile of
PRMT family members. Gene expression data obtained from
RNA-seq in undifferentiated ESCs revealed the high level
expression of PRMT1 in undifferentiated cells, suggesting its
dominant role in ESCs arginine methylation (Fig. 1D). Reverse
transcriptase (RT)-qPCR validation confirmed that PRMT1 is
highly expressed in ESCs and its expression remained constant
during neural differentiation showing a slight increase upon
RA treatment (Fig. 1E). Other type I PRMTs, responsible for
aDMA were less abundant in ESCs, but PRMT2, PRMT6, and
PRMT8 showed significantly increased gene expression in dif-
ferentiated neurons. In line with the unaltered sDMA level,
expression of type II PRMT5 was not changed (Fig. 1E).
Importantly, we found that asymmetric arginine dimethy-
lation of Histone 4 arginine 3 (H4R3me2a) also indicated
increased asymmetric arginine methylation upon differentia-
tion (Fig. 1F). H4R3me2a mark and the identified Sam68
methylation are deposited by PRMT1 and its closest paralog
PRMT8 [25, 34], however, their functional redundancy is not
understood yet. These results drew our attention to the
importance of PRMT1 and PRMT8 in neurogenesis. PRMT1
maintained a more or less even protein level during the
Figure 1. Asymmetric arginine methylation is changing in distinct stages of RA-induced neural differentiation. (A): Flow diagram of the
multistage differentiation procedure that involves: (I) undifferentiated stem cell culture, (II) embryoid body formation, (III) all-trans RA
treatment, and (IV) neuronal culture on poly-L-ornithin/laminin-coated plates. Indicated stages are shown with bright field microscopy.
Scale bar5 40 mm. (B): Typical single-cell voltage clamp and current clamp measurements of terminally differentiated (day 16) neurons.
Upper panel: Voltage-gated inactivating and noninactivating inward currents (from 230 mV) are marked on the figure. Lower panel:
Embryonic stem cell (ESC)-derived neurons were used in depolarizing current injection steps. Alkaline phosphatase trains with over-
shoot are shown. (C): Immunoblot analysis of different stages of neural differentiation. Samples were collected at day 0, 4, 8, 12, and
16 of neural differentiation. Anti-ASYM24 antibody recognizes proteins that contain arginines that are asymmetrically dimethylated.
Anti-SYM11 antibody recognizes proteins that contain arginines that are symmetrically dimethylated. GAPDH serves as a loading control.
(D): Genome browser view of the merge of mouse ESC RNA-seq, and RNA Pol and H3K27ac ChIP-seq activity on the indicated loci. (E):
Expression profile of PRMTs as detected by reverse transcriptase quantitative polymerase chain reaction. RNA samples were collected at
day 0 (I), day 4 (II), day 8 (III), and day 12 (IV). Gene expression data are expressed as a ratio of the indicated genes’ transcript relative
to Gapdh. (F): Total intranuclear levels of histone 4 arginine 3 asymmetric dimethylation as compared by indirect immunofluorescence,
on a cell-by-cell basis, by laser scanning cytometry. The columns show the means of the fluorescence intensity distribution histograms
obtained for G1 cells in four independent experiments (p .001). The bars on the columns are SDs. (G): Immunoblot analysis of differ-
ent stages of neural differentiation. Samples were collected at day 0, day 4, day 8 (6 RA treatment), and day 12 (6 RA treatment).
GAPDH serves as a loading control. (H): Localization of H4R3me2a, PRMT1, and PRMT8 (each in red) in stem cell derived neuronal cells
as detected by immunocytochemistry. Neurons were costained by anti-TUJ1 antibody (green). Arrows indicate the cytoplasmic localiza-
tion of PRMT1. Scale bar5 5 mm. ns, non significant; *, p .05; **, p .01; ***, p 0.001. Abbreviations: atRA, all-trans Retinoic Acid;
aDMA, asymmetric dimethylarginine; FBS, fetal bovine serum; LIF, leukemia inhibitory factor; MMA, monomethylarginine; PRMT, protein
arginine methyl transferase; bME, beta-mercaptoethanol; RA, retinoic acid; sDMA, symmetric dimethylarginine.
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course of RA-dependent neural differentiation, while PRMT8
was induced upon RA treatment and was present only in dif-
ferentiated neurons (Fig. 1G). H4R3me2a and PRMT8 showed
nuclear localization, while PRMT1 could also be detected in
the cytoplasm of differentiated neurons (Fig. 1H).
PRMT1 Is Responsible for Arginine Methylation in
ESCs and Affects Transcription
As a next step we established PRMT1 and PRMT8 knockdown
ESCs to get functional insights into the role of these two pro-
teins in neurogenesis. Although PRMT1 knockout ESCs were
established previously [17], a proper genetic control was not
available for comperative studies. Thus, we established PRMT1
and PRMT8 knockdown ESCs using shRNA-based gene silenc-
ing (Fig. 2A, 2B; Supporting Information Fig. S2A–S2F) in addi-
tion to PRMT1 knockout cells (Supporting Information Fig.
S2G). Analysis of asymmetrically arginine dimethylated pro-
teins using anti-ASYM24 antibody revealed hypomethylation
of certain cellular proteins in PRMT1-depleted ESCs (Fig. 2B;
Supporting Information Fig. S2G). PRMT1 was mainly localized
in the cytoplasmic fraction, however asymmetric arginine
methylation was more abundant in the nucleus (Fig. 2C; Sup-
porting Information Fig. S1C). ASYM24 decorated signal inten-
sity decreased in both fractions as the result of PRMT1
silencing. The total amount of PRMT1 mediated H4R3me2a
histone modification was also decreased (Fig. 2D), further
demonstrating the functional consequences of the loss of
PRMT1 activity and indicating the role of PRMT1 in the regu-
lation of chromatin. PRMT1-depleted or knockout cells
showed typical ESC morphology and positive staining for well-
established markers of pluripotency (Fig. 2E; Supporting Infor-
mation Fig. S2H).
To clarify the transcriptional consequences of the reduced
level of PRMT1 in ESCs, we carried out global transcriptional
analyses using RNA-seq. Pathway analysis clarified that the
165 differentially expressed genes are mainly related to cellu-
lar movement (Hspb1, Fgfbp1, Ctgf, Cyr61), proliferation and
p53-signaling (Camk2n1, Igfbp3, Smad7, Tpm1), tight junction,
and cytoskeletal elements (Myl9, Thbs1, Sepp1) (Fig. 2F; Sup-
porting Information Table 1). A role for PRMT1 in many of
these cellular function has been previously suggested in other
cellular model systems [35, 36]. Importantly, typical pluripo-
tency markers were not affected by the loss of PRMT1, sug-
gesting that PRMT1 in contrast to CARM1, is not required for
the maintenance of pluripotency [14]. Importantly, 39 out of
165 significantly regulated genes showed upregulation in
PRMT1 depleted ESCs versus control cells, suggesting the loss
of repression on these genes in hypomethylated cells (Fig.
2F). Taken together, data obtained from gene-expression anal-
ysis indicate that PRMT1, beside its known transcriptional
coactivator function, has a repressive feature on a set of
genes, which might be relevant in various cellular functions.
Importance of arginine methylation of coregulators was
demonstrated by others [37, 38]. It has been also shown that
methylation of Arg3 on H4 tail peptides facilitates P300-
mediated histone acetylation in vitro [21–23]. In order to see
whether P300 and PRMT1 are present in one complex in ESCs
we carried out coimmunprecipitation experiments. Several
asymmetrically arginine methylated proteins were coimmun-
precipitated along with P300 but not with the isotope control
(Fig. 2G). Moreover, the asymmetric arginine methylation of
these proteins were PRMT1-dependent.
To understand the contribution of PRMT1-mediated argi-
nine methylation in P300-mediated transcriptional and epige-
netic program of ESCs we determined the P300 cistrome in
the presence and absence of PRMT1. We could identify 3,420
consensus P300 binding sites present in both D3 and E14 con-
trol ESCs (Supporting Information). Motif analysis revealed
that P300 is mainly recruited to the stem cell specific tran-
scription factor Oct3/4, Sox2, Klf4, Esrrb, and Nanog (Fig. 2H).
Considering only those P300 bindings that were detectable
and significant in both D3 and E14 cells between control and
PRMT1-depleted cells we could identify only approximately 90
genomic regions. Half of these regions showed increased
Figure 2. PRMT1 is responsible for arginine methylation in embryonic stem cells (ESCs) and affects transcription. (A): Genome browser
view of RNA-seq data comparing the PRMT1 coding locus in the indicated ESCs. Biological duplicates are shown. (B): Immunoblots of
protein samples from the indicated D3 ESCs lines probed for expression of PRMT1, ASYM24, and OCT3/4. ACTIN was used as a loading
control. (C): WB analysis of subcellular fractionations. Cytoplasmic (CYTO) and nuclear fractions (NUC) of undifferentiated shSCR and
shPRMT1 ESCs were isolated and probed for PRMT1 and ASYM24. GAPDH is a loading control for cytoplasm. (D): Total intranuclear lev-
els of H4R3 asymmetric dimethylation as compared by indirect immunofluorescence between undifferentiated shSCR and shPRMT1
ESCs. (E): Characterization of unmodified D3, shSCR, shPRMT1, and shPRMT8 ESCs. Expression of ESC marker SSEA-1 and OCT3/4 were
determined by immunocytochemistry. AP staining show undifferentiated colonies. Chromosome counting was performed as described in
the Supporting Information. Scale bar5 40 mm for Native, SSEA-1, and Oct3/4; 200 mm for AP, and 10 mm for karyotype. (F): Heatmap
display of gene expression data of D3, E14, and PRMT12/2 ESCs, normalized to D3 and shSCR vs. shPRMT1 ESCs, normalized to shSCR.
Total RNA was isolated from undifferentiated ESCs and RNA-seq experiment was carried out to determine those genes that were signifi-
cantly (FDR 0.1 and Log2FC 1.2) upregulated (n5 39, red) or downregulated (n5 126, blue) in both PRMT12/2 and shPRMT1 ESCs
vs. their control. See also Supporting Table 1. (G): Asym24 immunoblot of P300 interacting complex. Nuclear extract of control and
PRMT1-depleted cells were used to coimmunprecipitate proteins with anti-P300 or IgG isotype control. (H): De novo identification of
motifs under peaks from P300 ChIP-seq data using Homer. Top 1,000 binding sites in each samples and the matrix files of the best
motifs (highest score) were used for forced motif search in D3 shSCR and E14 shSCR P300 ChIP-seq samples. % refers to the ratio of
peaks having the given motif. (I): Histogram of PRMT1-dependent P300-binding. P300 ChIP-seq was carried out in shSCR and shPRMT1
D3 and E14 ESCs. Regions showing significantly different (p< .05) P300 occupany between shSCR and shPRMT1 in both D3 and E14
were identified by differential binding analysis, resulting 40 upregulated (red) and 47 downregulated (black) P300 occupied genomic
regions in shPRMT1 (dashed line) vs. shSCR (continual line). (J): Hematoxylin and eosin staining of teratoma derived from PRMT12/2
ESCs. Cells were injected into lower leg of SCID mice at a concentration of 5 3 106 cells per ml. After 4–6 weeks the teratoma were
surgically dissected, fixed, embedded in paraffin, and sectioned. Scale bar5 200 mm. (K): Ingenuity pathway analysis of genes differen-
tially expressed at day 4. Microarray experiment was carried out using RNA samples obtained from shSCR and shPRMT1 ESCs differenti-
ated for 4 days. Top biological functions predicted by the software and p values are shown. ns, non significant; **, p .01.
Abbreviations: AP, alkaline phosphatase; PRMT, protein arginine methyl transferase; CYTO, cytoplasmic; NUC, nuclear; RAR, Retinoic Acid
Receptor; RXR, Retinoid X Receptor; WB, Western blot.
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P300 occupancy in PRMT1 knockdowns (Fig. 2I). We could
identify only few examples where PRMT1-dependent P300
recruitment were coupled to differential gene expression
(e.g., Igsf21, Ankrd35, Sema3e, Colec12). These results suggest
that, at least in undifferentiated ESCs, P300 occupancy is
dominantly PRMT1-independent.
We next evaluated the differentiation potential of the
PRMT1-depleted cells. Genome-wide comparison and RT-qPCR
validation of spontaneously differentiated control and hypo-
methylated cells showed that classical lineage markers of
endoderm, mesoderm, and ectoderm were similarly induced
upon spontaneous differentiation (Supporting Information Fig.
S3A–S3C). Injection of PRMT12/2 ESCs into immunodeficient
mice resulted in teratoma formation with obvious differenti-
ated structures from all three germinal layers, excluding the
possibility that residual PRMT1, present in knockdown cells, is
sufficient for differentiation (Fig. 2J). PRMT12/2 cells were
also able to differentiate to Vimentin1 mesenchymal cells
and TroponinC1 cardiomyocytes (Supporting Information Fig.
S3D), suggesting that cells can undergo differentiation to vari-
ous cell types in the absence of PRMT1.
To identify differentiation-related signaling pathways that
were affected in hypomethylated cells, we compared the
gene expression profile at day 4 of differentiation. Pathway
analysis based on altered expression of Dusp1, Fos, Smad3,
and Tgfb3 predicted RXR:LXR and RXR:RAR activation as one
of the top canonical pathways being reactivated in the
absence of PRMT1 (Fig. 2K).
PRMT1 Selectively Modulates the Regulation Retinoid
Target Genes
RA, acting through the activation of RXR:RAR, is a general
inducer of ESCs differentiation [39]. In order to characterize
the early response of RA in PRMT1-depleted cells, we per-
formed genome-wide comparison of gene expression in RA-
treated EBs (day 4). 12 hours of RA treatment changed the
expression of 127 genes in control cells and 492 genes in
hypomethylated cells (Fig. 3A). While most of the known reti-
noid targets, such as Cyp26a1, Dhrs3, Dleu7, Rbp1, Stra8
were induced to the same degree in PRMT1-depleted and
control cells; Hoxa1, Hoxb1, Stra6, Pmp22, and Spsb1 also
under RA control [40, 41], showed higher induction in hypo-
methylated cells (Fig. 3B; Supporting Information Figs. S4,
S5A, S5B). Importantly, many genes (e.g., Foxd3, Otx2)
showed more pronounced RA-induced repression in PRMT1
knockdown cells, while Zfp428 and Fgf5 were only repressed
in PRMT1-depleted cells (Fig. 3B; Supporting Information Fig.
S4). These results suggest a gene-selective regulatory effect of
PRMT1 in the RA response of ESCs.
To further investigate the selectivity at the promoter level,
we transfected ESCs with the Hoxb1 promoter, containing the
DR2 RA-response element, linked to a luciferase reporter
gene [41] (Supporting Information Fig. S5C). Transient overex-
pression of PRMT1 resulted in a decrease in basal transcrip-
tion level of Hoxb1 (Fig. 3C). To a lesser extent Pmp22 and
Spsb1 enhancers were also suppressed in the presence of
PRMT1. The ligand induced retinoid response of Hoxb1 and
Spsb1 were also decreased (Fig. 3D). Accordingly, in the
absence of PRMT1, RA-dependent transcriptional activity was
markedly increased (Fig. 3E). Importantly, PRMT1 had no
effect in case of a synthetic canonical DR2 response element
(Fig. 3F), suggesting a context-dependent and promoter-
selective effect of PRMT1 in the regulation of retinoid
response.
P300 has been implicated as a regulator of retinoid
response in F9 cells [42, 43]. In order to see, whether
PRMT1-modulated, RA-induced gene expression correlates
with P300 binding, we first determined the RA-dependent
P300 cistrome in ESCs. Upon RA treatment there was a three-
fold reduction in the number of P300 binding sites in control
cells (Fig. 3G) and also the occupancy was substantially
decreased (Fig. 3H). We could observe similar P300 redistribu-
tion in the PRMT1 knockdown cells (Supporting Information
Fig. S6A).
Figure 3. PRMT1 acts as selective regulator of retinoid regulated genes. (A): Proportional Venn-diagram that represents the overlap
between gene expression changes in retinoid induced differentiation of control (shSCR) and PRMT1-depleted cells as determined by micro-
array. EBs at day 4 were treated with DMSO or 5 mM RA for 12 hours. (B): Gene expression changes from control and PRMT1-depleted
cells upon RA treatment. Cells were spontaneously differentiated for 4 days and then treated with RA or vehicle for 12 hours. Fold induc-
tions were calculated from per chip normalized microarray data (vehicle vs. RA treated, n5 3 per condition) for each gene. Calculated val-
ues of PRMT-depleted cells then were normalized by values of the control. Red line shows when the induction is equal in both cell types
(e.g., Cyp26a1, Dhrs3). (C): PRMT1-dependent repression of RA-induced enhancers. pcDNA.3.1-PRMT1 (PRMT1) or empty pcDNA3.1
(empty) plasmids were cotransfected with NHf290-Hoxb1-Luciferase plasmid [41] or Pmp22 and Spsb1 enhancers cloned into Luciferase
encoding vector (Supporting Information Fig. S5C). Luciferase signal intensity was determined and normalized to bgal signal. (D): RA-
dependent activation of Hoxb1 promoter and Spsb1 enhancer. Indicated plasmids were cotransfected with NHf290-Hoxb1-Luciferase or
Spsb1-Luciferase plasmid and cells were treated with RA. (E): NHf-Hoxb1-Luciferase plasmid was transfected into shSCR or shPRMT1 cells.
Cells were treated with RA for 24 hours using the indicated ligand concentration and normalized luciferase values determined. (F): DR2 RA
response element containing luciferase plasmid was cotransfected with pcDNA3.1-empty or pcDNA3.1-PRMT1 expression vector. Cells
were treated with RA for 24 hours using the indicated concentrations. Normalized luciferase activity was determined and the mean of trip-
licate determinations6 SD is shown. (G): Area-proportional Venn-diagram of RA induced P300 redistribution. Cistromes of P300 were
determined in control (vehicle) and RA-treated (1 mM, 24 hours) D3 shSCR ESCs by ChIP-seq. (H): Histogram of the genome-wide occu-
pancy of common P300 peaks (n5 1,103) in vehicle and RA-treated (1 mM, 24 hours) cells, centralized to common P300 occupied regions.
(I): De novo identification of motifs under P300 peaks from ChIP-seq data using Homer. P300 occupied genomic regions were identified in
promoter regions of the 398 PRMT1-sensitive RA-regulated genes (A). % of targets refers to the ratio of peaks having the given motif. (J):
Genome browser view of the indicated ChIP-seq data on PRMT1-sensitive and PRMT1-insensitive loci. H3K27ac, RXR, and P300 ChIP-seq
data were obtained from untreated ESCs and cells treated with 1 mM RA for 24 hours. (K): H4R3me2a ChIP-qPCR signals on the indicated
individual enhancers (J) as detected in untreated shSCR, shPRMT1, and shPRMT8 ESCs. (L): P300 ChIP-qPCR signals on the indicated indi-
vidual enhancers as detected in untreated shSCR, shPRMT1, and shPRMT8 ESCs. (M): RAR, RXR, P300, and Oct3/4 ChIP-qPCR signals on
the Hoxa1 enhancer (Fig. 3J) in undifferentiated and RA-treated ESCs. (N): P300 and Oct3/4 ChIP-qPCR signals on the Otx2 enhancer (J) in
undifferentiated and RA-treated ESCs. ns, non significant; *, p .05; **, p .01; ***, p .001. Abbreviations: atRA, all-trans Retinoic Acid;
ChIP, chromatin immunoprecipitation; DR, direct repeat; EB, embryoid body; Luc, luciferase; PRMT, protein arginine methyl transferase;
RA, retinoic acid; RAR, Retinoic Acid Receptor; RXR, Retinoid X Receptor; wt, wild-type; veh, vehicle.
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P300 occupancy highly correlates with active enhancers
[44]. As a next step, we identified the P300 occupied genomic
regions in the close proximity of the 398 PRMT1-sensitive RA
regulated genes (Fig. 3A) to identify putative common master
regulators of these genes. The motif analysis of these genomic
regions revealed binding site enrichment of Oct3/4, Sox2, and
Nanog beside the RAR:RXR bound NR half site (Fig. 3I). Inter-
estingly, comparison of promoter regions of PRMT1-insensitive
(e.g., Cyp26a1, Dleu7, Rbp1, Stra8, Dhrs3) and PRMT1-
sensitive (e.g., Hoxa1, Hoxb1, Spsb1, Pmp22, Stra6 and Foxd3,
Otx2, Zfp428, Fgf5) genes showed remarkable differenes in
the overall binding site enrichment for Oct3/4, Sox2, and
Nanog (Fig. 3J). Moreover, P300 redistribution could also only
be detected on promoter region of PRMT1-sensitive genes
(Fig. 3J; Supporting Information Fig. S6B, S6C), suggesting that
P300 and PRMT1 are likely to coregulate such transcriptional
“hotspots.”
To get further mechanistic evidence that these regions are
targeted by PRMT1, we determined the H4R3me2a signal in
the proximity of PRMT1-sensitive and insensitive genes. As
shown in Figure 3K and Supporting Information Figure S6D,
Hoxa1, Spsb1, Otx2, and Zfp428 enhancers showed clear
PRMT1-dependent enrichment of H4R3me2a at these regions,
while P300 recruitment was not altered (Fig. 3L; Supporting
Information Fig. S6E). RA-dependent changes showed no clear
tendency between the compared regions (Supporting Informa-
tion Fig. S6F, S6G). In accordance with the P300 ChIP-seq data
ChIP-qPCR validation confirmed that RA treatment selectively
increased the recruitment of P300 to the promoter of Hoxa1
but not to Cyp26a1 or Dhrs3 (Fig. 3M; Supporting Information
Figure 4. PRMT8 is a retinoic acid receptor regulated gene and acts as a coactivator of retinoid signaling. (A): Heatmap analysis of
gene expression microarray data of PRMT family members. Values are normalized to undifferentiated ESCs (day 0). (B): Ligand response
of PRMT8 upon RA treatment at various time points. Undifferentiated ESCs were treated for the indicated times with 1 mM RA.Values
are expressed as mean of technical triplicates6 SD of the mean. (C): TK-Luc-PRMT8 was constructed by cloning 300 bp promoter region
of PRMT8, containing the DR0 element, into a TK-Luc-empty plasmid. ESCs or HEK293T cells were transiently transfected and treated
with 0.1 mM RA for 24 hours. Above the identified DR0 element and surrounding sequence is shown. (D): Dose response curves of
Hoxb1 and Cyp26a1 as measured by reverse transcriptase quantitative polymerase chian reaction. shSCR and shPRMT8 ESCs were
treated with the indicated concentrations of RA for 24 hours. EC50 values are shown. (E): TK-Luc Hoxb1 or TK-Luc Cyp26a1 enhancer
traps were constructed by cloning 300 bp regions of Hoxb1 and Cyp26a1, respectively (Supporting Information Fig. S5D). ESCs were
transfected along with pCMV-Tag2-empty or pCMV-Tag2-PRMT8 expression plasmid. Cells were treated with RA for 24 hours using the
indicated ligand concentrations. (F): Hoxb1 (DR2) or Cyp26a1 (DR5) enhancer trap was transfected into shSCR or shPRMT8 ESCs. Cells
were treated with RA for 24 hours using the indicated ligand concentrations. (G): 2x DR2 retinoic acid response element containing
luciferase plasmid was transfected into shSCR or shPRMT8 ESCs. Cells were treated with RA for 24 hours using the indicated ligand con-
centrations. (H): 2x DR2 retinoic acid response element containing luciferase plasmid was transfected into PRMT1 knockout (P12/2) or
shPRMT8 PRMT1 double “knockout” (P12/2 shP8) ESCs. Cells were treated with RA for 24 hours using the indicated ligand concentra-
tions. Normalized luciferase values were determined, and the mean of three determinations6 SD are shown. ns, non significant; *,
p .05; **, p .01; ***, p .001. Abbreviations: ESC, embryonic stem cell; EC50, half maximal effective concentration; DR, direct
repeat; P12/2 /shP8, PRMT, protein arginine methyl transferase; PRMT1 knockout/shPRMT8; RA, retinoic acid.
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Fig. S6H, S6I). Spsb1 already showed increased P300 binding
which was not further enhanced (Fig. 3J) As expected, Otx2
and Zfp428 showed decreased P300 binding upon RA treat-
ment (Supporting Information Fig. S6H, S6I). Interestingly, we
detected a constant Oct3/4 binding on the Hoxa1 enhancer
even after 24 hours of RA treatment (Fig. 3M), while Oct3/4
occupancy has significantly decreased on the enhancer of
repressed Otx2 (Fig. 3N). These data collectively suggest that
RA regulated enhancers can be grouped into two categories,
PRMT1 sensitive and insensitive ones with distinct
Figure 5.
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transcription factor complexes. The PRMT1 sensitive ones are
characterized by PRMT1-dependent H4R3me2a, Oct3/4, Sox2,
Klf4, or Nanog (OSKN), and P300 binding.
PRMT8 Is a RA Inducible Coactivator of Retinoid
Signaling
As it was shown in Figure 1C, RA treatment resulted in
changes in asymmetric arginine methylation. Comparison of
the expressional profile of PRMTs upon short-term RA-induc-
tion of day 4 EBs revealed the early upregulation of PRMT8
(Fig. 4A, 4B). To prove that PRMT8 is regulated in a RA-
dependent manner, ESCs were treated with RAR and RXR spe-
cific ligands. PRMT8 expression could be induced by RAR-
specific ligand AM580, but the RXR-specific LG268 had no
effect (Supporting Information Fig. S7A). Moreover, RA-
dependent induction of PRMT8 showed a similar time- and
dose dependence as Hoxb1 and Cyp26a1, well established
direct targets of the retinoid signaling pathway (Fig. 4B; Sup-
porting Information Fig. S7B, S7C) [45]. A recently published
RAR ChIP-seq in F9 cells [46] allowed us to identify a putative
enhancer in the promoter region of PRMT8. This region
(21,400 to 21,450 relative to transcription start site) con-
tains a direct repeat with no spacer (AGGTCAAGGTCA, DR0)
that can bind RAR:RXR (Supporting Information Fig. S7D).
Transfecting an enhancer trap vector that contains this 300-bp
genomic region of the PRMT8 promoter, we could validate
functionally the element in response to RA treatment in ESCs
(Fig. 4C). These results confirm PRMT8 as a direct RA-
regulated gene. Importantly, using the same construct, we
could not detect RA-dependent induction of PRMT8 in
HEK293T cells (Fig. 4C). This suggests a more complex sce-
nario, where the presence of additional cell-type specific fac-
tors are required for proper enhancer activity.
PRMT1 and PRMT8 exhibit high sequence similarities [25],
thus we were interested whether loss of PRMT8 may also
affect retinoid response. Unexpectedly, loss of PRMT8 had an
inhibitory effect on the retinoid response. In a dose-curve
comparison of Hoxb1 and Cyp26a1, induction loss of PRMT8
resulted in a significant increase in the half maximal effective
concentration (EC50) value of RA (Hoxb1: 4.8 to 860 nM,
Cyp26a1: 148 to 808 nM) (Fig. 4D). To validate the coregula-
tory function of PRMT8 in RAR:RXR signaling, enhancer trap
vectors of Hoxb1 or Cyp26a1 RARE were used in a luciferase
reporter assay (Supporting Information Fig. S5D). As shown in
Figure 4E, ESCs transfected with the reporter alone showed
RA-dependent induction, which was further stimulated by
cotransfection of PRMT8. In contrast, loss of PRMT8 resulted
in a decreased signal intensity (Fig. 4F). Moreover, the
decrease observed in PRMT8-depleted cells could be restored
by the overexpression of PRMT8 (Supporting Information Fig.
S7E). In contrast to PRMT1, loss of PRMT8 also resulted in a
decrease in the signal when an artificial canonical DR2 con-
taining reporter was used (Fig. 4G), suggesting that PRMT8 is
a general coactivator of RA signaling. To dissect the role of
PRMT1 and PRMT8, we used PRMT8-depleted cells on
PRMT12/2 background (double knockdown). The inhibitory
effect in the absence of PRMT8 was found to be independent
of the presence of PRMT1 (Fig. 4H).
PRMT1 and PRMT8 Regulate Subtype Specification of
Differentiating Neural Cells
Next, we studied if loss of either or both PRMT1 and/or
PRMT8 has consequences on RA-induced neuronal differentia-
tion and/or gene expression. The stability of the knockdowns
has been confirmed in differentiated neurons (Fig. 5A; Sup-
porting Information Fig. S8A). Importantly, loss of either
PRMT1 or PRMT8 resulted in hypomethylation of neurons as
detected by anti-ASYM24 antibody (Fig. 5A).
At day 12 of differentiation, the knockdown derived neural
cells showed similar morphology and high expression of neural
markers, such as Lhx1, Pax6, or Tuj1 to wild-type cells (Fig. 5B;
Supporting Information Fig. S8B). PRMT1 knockout cells could
also differentiate to TUJ11 neurons (Supporting Information
Fig. S8C), further demonstrating that PRMT1 is not an essential
factor in early neural differentiation. In contrast, genome-wide
analysis of day 16 samples revealed dysregulation of several
genes in PRMT1- or PRMT8-depleted cells (Fig. 5C). Loss of
either PRMT1 or PRMT8 resulted in mainly the downregulation
of genes. Interestingly, grouping of the differentially expressed
genes identified that a large fraction of the genes (473 out of
Figure 5. PRMT1 and PRMT8 affect neuronal differentiation. (A): Immunoblot analysis of day 16 differentiated neurons derived from the indicated
cell types probed for the indicated proteins. (B): TUJ1-staining of day 12 neurons. DAPI costaining was used to visualize cell nuclei. Scale bar, black5 80
mm, white5 40 mm. (C): Heatmap display of microarray gene expression data obtained from D3, shSCR, shPRMT1, and shPRMT8-derived neurons at
day 16, normalized to D3 neurons. Hierarchical cluster analysis is shown. Blue color indicates downregulated, red shows upregulated genes compared to
D3-derived neurons. (D): Area-proportional Venn-diagram compares PRMT1-dependent and PRMT8-dependent gene expression changes in differenti-
ated neurons. Cells differentiated for 16 days were used for microarray experiments. Significantly changing genes (FC 1.5, p< .05) were determined
by comparing shSCR vs. shPRMT1 or shSCR vs. shPRMT8-derived neurons. (E): Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
validation of expression level of Phox2b and Gfra2 in the indicated cells. (F): Coimmunoprecipitation of PRMT1 by full-length FLAG-PRMT8. HEK293Tcells
were transfected with the indicated constructs. Anti-MYC antibody was used for immunoblot analysis. (G):Mitotic index of day 8 embryoid bodies were
evaluated and compared by counting mitotic figures on H&E-stained slides. A representative mitotic figure and a rosettoid structure are shown. Average
number of mitotic figures per 20 consecutive HPF (340 magnification) is shown. (H): Cell cycle analysis of the differentiated shSCR, shPRMT1, and
shPRMT8 knockdown cells. Nuclei of agarose embedded and permeabilized cells were stained with propidium iodide and measured by laser scanning
cytometry. In the left panel, the bar charts show the percentage of cells in the different cell cycle phases. Error bars: SD calculated from n 3 independ-
ent experiments. The dot plots and DNA histograms (right panel) show one representative measurement for each cell line. In the case of shSCR and
shPRMT1 neurons, the difference between the ratio of nondividing and dividing cells ((G11G0)/(S1G21M)) was statistically significant (p5 .029;
Mann Whitney rank sum test). (I): Ratio of cells with recorded fast calcium signal. Recordings and analysis has been carried out in the indicated embry-
onic stem cell-derived neural cultures. A representative experiment is shown (>200 measured neurons/condition). (J): Counts of calcium signals per
minute normalized to the number of cells with positive calcium signal. A representative experiment is shown (>200 measured neurons/condition). (K):
Synchronous activity among the cells of the PRMT1 knockdown cultures. Synchronous events labelled with asterisks. Calcium imaging records of six ran-
domly chosen ROIs (regions of interests) per condition are shown. ns, non significant; *, p .05; **, p .01. Abbreviations: HPF, high-power fields; IP,
immunoprecipitation; PRMT, protein arginine methyl transferase; WB,Western blot.
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947) showed similar dysregulation in both knockdown cell types
(Fig. 5D). We validated Phox2b (Paired-Like Homeobox 2b), an
important transcription factor of neural specification [47] and
Gfra2 (GDNF Family Receptor Alpha), a regulator of neurite out-
growth [48] by RT-qPCR (Fig. 5E). Gene expression data sug-
gested that PRMT1 and PRMT8 might act together in the
regulation of these genes. Indeed, as shown in Figure 5F, coim-
munoprecipitation studies confirmed that the two proteins are
likely present in one complex.
To further evaluate the characteristics of early progenitors
and differentiated neurons, we compared the ratio of dividing
versus nondividing cells. In the progenitor phase, mitotic index
of PRMT1-depleted cells were significantly higher (Fig. 5G). Cell
cycle analysis of differentiated cells at day 16 also suggested
that PRMT1-depleted cells show significantly higher number of
nonterminally differentiated, dividing cells (Fig. 5H).
Importantly, expression level of ESC markers and meso-
derm, endoderm, or early ectoderm lineage markers were simi-
larly low in neurons differentiated from hypomethylated cells
(Supporting Information Fig. S8D–S8F), further confirming that
loss of PRMT1 and PRMT8 do not inhibit the neural differentia-
tion per se. Ingenuity pathway analysis of the 473 genes (Fig.
5D) implicated PRMT1 and PRMT8 in neuronal synaptic forma-
tion, glutamate receptor signaling, and axonal guidence (Sup-
porting Information Fig. S8G). Next, we studied functional
properties of PRMT1- or 8-depleted neurons by calcium imag-
ing. This method allowed us to compare >200 cells per condi-
tion. Importantly, the frequency of calcium peaks and the
frequency of action potentials recorded in the same neuron
showed a significant correlation (Supporting Information Fig.
S9A), in accordance with earlier observations [28, 49, 50].
Approximetly 50% of the cells showed neural activity in the
control and PRMT8 knockdown cells, while in the PRMT1-
depleted cell culture the rate of active cells was almost 100%
(Fig. 5I). As a remarkable difference, we found that the fre-
quency of fast calcium signals per active cells was dramatically
dropped in PRMT8-knockdowns, suggesting an important role
of PRMT8 in the establishement of neuronal excitability (Fig.
5J). Another interesting observation was the frequent occur-
ance of synchronous activity among the cells of the PRMT1
knockdown cultures (see synchronous events labeled with
asterisks in Fig. 5K).
PRMT8 Regulates Distinct Set of Genes and Loss of
PRMT8 Is a Marker of Glioblastoma Multiforme
The gene expressional analysis also revealed that several
genes, such as Cxcr4, Dhfr, or Efemp1 previously linked to glial
differentiation and gliomagenesis [51–53] were expressed dif-
ferentially only in PRMT8 knockdown cells (Fig. 6A, 6B). Using
PRMT1-PRMT8 double knockdown cells, we found that these
genes are PRMT8-dependent (Fig. 6C–6E).
We used a large number of human primary glioma samples
to confirm that PRMT8-dependent Cxcr4 and Efemp1 indeed
show dysregulation in glioblastoma multiforme (GBM) (Fig. 6F).
Prompted by this finding and a result of a recent study that
linked Single-nucleotide polymorphism (SNP) variation in
PRMT8 promoter to familial gliomagenesis [54], we also deter-
mined expression of PRMT8 in these samples. Very strikingly,
PRMT8 itself showed a substantially lower expression level in
GBM samples, while PRMT1 did not show a difference between
the groups (Fig. 6F). These data indicate that loss of PRMT8 and
genes regulated by it are putative markers in GBM and might
participate in its development.
DISCUSSION
We combined genetic approaches with genome-wide gene
expression technologies to unravel the contribution of PRMT1
and PRMT8 to in vitro neuronal differentiation. We propose
the following model (Fig. 6G). There are two distinct phases
during the course of neural differentiation: in early stages
only PRMT1 is expressed. PRMT1 acts as a selective repressor
of a large set of RA-induced genes (Hoxa1, Hoxb1, Pmp22,
and Spsb1). The promoter regions of these PRMT1-sensitive
genes are regulatory hotspots as they are occupied by OSKN
and show P300 recruitment upon RA treatment. Genes, such
as Otx2 and Zfp428 that are active in ESCs and occupied by
OSKN and P300 are also influenced by PRMT1. This way
PRMT1 arms the cells with a negative feedback mechanism to
limit RA’s effect on a subset of target genes.
Subsequently, the RA signal directly induces the expres-
sion of PRMT8. In this late stage, PRMT8 collaborate with
PRMT1 but PRMT8 might also exist as a homodimer [25].
PRMT8 in such complex acts as a coactivator that potentiates
Figure 6. Loss of PRMT8 results in a gene expression profile that resemble neurological disorder. (A): Heatmap visualization of microar-
ray data of the indicated glioma-releated markers in ES-derived neurons. Cells differentiated for 16 days were used for microarray
experiments, and data were normalized to wild type D3-derived neurons. (B): Gene expression level of Cxcr4 and Dhfr as measured by
reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) in day 16 ESC-derived neurons. (C): Gene expression level of
PRMT8 in PRMT12/2 shSCR vs. PRMT12/2 shPRMT8 ESC-derived neurons as measured by RT-qPCR at day 12 of differentiation. (D):
Immunoblot analysis of TUJ1 in different stages of PRMT12/2 shSCR vs. PRMT12/2 shPRMT8 neural differentiation. Samples were col-
lected at day 8, 12, and 16. GAPDH serves as a loading control. (E): Gene expression level of indicated genes in PRMT12/2 shSCR vs.
PRMT12/2 shPRMT8 ESC-derived neurons as measured by RT-qPCR at day 14 of differentiation. (F): Gene expression level of Cxcr4,
Efemp1, PRMT1, and PRMT8 as measured by RT-qPCR. Human normal (n5 54) and glioblastoma multiforme (GBM) (n5 83) samples
were compared. Each dot represents an individual sample. (G): Proposed model of PRMT1 and 8’s action on early and late stage of neu-
ronal differentiation. PRMT1 is expressed in early stage and acts as a selective repressor of retinoic acid induced gene expression.
PRMT1-sensitive (e.g., Hoxb1) regions are occupied by Oct3/4, Sox2, Klf4, or Nanog, while PRMT1-insensitive sites (e.g., Cyp26a1) are
not enriched for these transcription factors. P300 is also selectively recruited to the PRMT1-sensitive sites only. H4R3me2a marks can
be detected in a PRMT1-dependent manner on the close proximity of all these PRMT1-sensitive enhancers. PRMT1-sensitive, retinoic
acid (RA)-repressed genes (e.g., Otx2) also show P300 and OSKN occupancy in untreated ESCs. In the late stage, RA-induced PRMT8 are
present in a complex with PRMT1 but PRMT8 might also exist as a homodimer [25]. PRMT8 in such complexes acts as a coactivator
that potentiates retinoid response. Hox-genes, Mapt and Phox2b are regulated by both PRMT1 and PRMT8. Pathway analysis predicts
REST, MAPT, APP, PSEN1 as upstream regulators responsible for dysregulated gene expression. PRMT8 has a PRMT1-independent regula-
tory potential as well, affecting gliomagenesis-related genes, such as Cxcr4, Dhfr, or Efemp1. ns, non significant; *, p .05; **, p .01;
***, p .001. Abbreviations: ESC, embryonic stem cell; PRMT, protein arginine methyl transferase; RARE, retinoic acid response
element.
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retinoid response. In this way PRMT1 and its closest paralog
PRMT8 integrate the morphogenic RA signal in a temporal
manner acting as a rheostat. Loss of PRMT1 or PRMT8 results
in mostly similar changes in neural specification, but PRMT1
and PRMT8 have independent regulatory potential as well.
PRMT1 has been previously identified as a ubiquitously
expressed secondary coactivator for nuclear receptors. It has
been also shown to bind the activation domain (AD2) of pri-
mary coactivators and enhance transcription [10]. In contrast
to this, our results now show a repressive function of PRMT1,
confirming in principle the findings of previous studies provid-
ing evidence for corepressor roles for PRMT1 in different cel-
lular context [55, 56]. These opposing roles in gene expression
regulation are not unique to PRMT1, similar phenomena have
been reported in case of other coactivators as well [57].
Gene and enhancer selectivity is also a novel and striking
feature of PRMT1, however the exact mechanism remains
unclear. Strikingly, PRMT1-sensitive sites show characteristics
of cell-type specific regulatory hotspots [58]: key transcription
factors, such as Oct3/4, Sox2, Klf4, and Nanog appear to be
enriched and mark these genomic regions. Importantly, the
coactivator P300 is also selectively recruited to these sites
upon RA treatment, providing further evidence to the exis-
tence of distinct epigenetic states between PRMT1-sensitive
and -insensitive sites. We found no indication that loss of
PRMT1 would affect P300 recruitment to these hotspots, but
we could detect a remarkable decrease in the level of
H4R3me2a mark at these sites in PRMT1-depleted cells, sug-
gesting the presence of PRMT1 at these genomic regions.
PRMT1-insensitive regions did not show PRMT1-dependent
H4R3me2a enrichment, however few exceptions could be
noticed (e.g., Rarb). Due to the lack of reliable ChIP-grade
anti-PRMT1 antibody, we could not get reproducible data so
far which would provide direct evidence for the presence of
PRMT1 at these sites though. A potential mechanism for the
enhancer selective effect of PRMT1 is that P300 or a member
of this protein complex is arginine methylated and this affects
its coactivator function. This scenario would also explain why
only P300 recruiting genomic regions are PRMT1-sensitive.
Such arginine methylation-dependent regulation of CBP has
been demonstrated by others [37, 38], and we also could
detect the presence of arginine methylated proteins in the
P300 complex. Further studies will be required to evaluate
this possibility in neuronal differentiation.
The result of loss of PRMT1 function in differentiating
neurons is altered gene expression. Gene expression data
obtained can be used in further studies to mechanistically
describe the PRMT-dependent transcriptional network in neu-
rogenesis. Importantly, the detected gene expression differen-
ces could be linked to various functional defects. First, we
found that loss of PRMT1 resulted in a delay in the cell cycle
exit and elevated number of mitotically active cells. These
findings are in line with a study which has identified the dom-
inantly PRMT1-mediated H4R3me2a as a marker of post-
mitotic neurons [59].
A recent study identified methylation of brain sodium
channel Nav1.2 in response to seizures [60]. Our preliminary
comparison of electrophysiological properties of the knock-
down cells led us to the conclusion that PRMT1 and PRMT8
are likely to be responsible for the proper function of ion
channels. Further in vitro and animal studies will be required
to identify more precisely the functional consequences of loss
of these PRMTs.
Dysregulation of RA signaling has also been implicated in
disease emergence and progression [61]. It is an intriguing
question whether PRMT1 and PRMT8 are involved in patho-
logical conditions of the brain as well. Our pathway analysis
indicates a role of PRMT1 and PRMT8 in microtubule-
associated protein tau-, amyloid beta A4 protein-, presenilin
1-, and brain-derived neurotrophic factor- related pathways.
Moreover, several genes showing dysregulated expression in
knockdowns have been also identified in a recent study as
potential markers of human AD [62] (Supporting Information
Fig. S9B, S9C). As PRMT1 or PRMT8 expression has not been
investigated in such disease conditions it is still very tentative
to suggest PRMT1 and PRMT8 in the progression of AD. How-
ever the observed gene expression pattern calls for further in
vivo correlative as well as mechanistic studies.
A previous comparison of mammalian PRMTs revealed
that PRMT1 and PRMT8 share the highest degree of identity
within this enzyme family [25]. Not only the amino acid
sequence of the two proteins but also the intron-exon boun-
daries are well conserved, suggesting that PRMT8 evolved by
the duplication of PRMT1. Importantly, a recent study demon-
strated that despite the similarities, PRMT1 and PRMT8 have
nonredundant functions in the neural development of Zebra-
fish [63], suggesting that PRMT8 has acquired novel functions
since its duplication. Our genome-wide screen and double
knockdown experiments also provide evidence of a PRMT1-
independent program of PRMT8.
Dysregulation of RA signaling has been also implicated in
progression of different subtypes of cancers [64]. In a recent
study, upregulation of PRMT1 has been reported in glioma tis-
sues and glioma cell lines [65]. In order to revisit this issue
we used a large patient cohort and found that the RNA levels
of PRMT8 are almost completely downregulated in glioma tis-
sues. A trivial explanation may be that PRMT8, a highly spe-
cific neural marker, is not expressed in astrocyte-derived
tumors [66]. Alternatively, loss of PRMT8 positively affects
astrocyte differentiation, resulting in a shift in cell fate com-
mitment. Further in vivo and in vitro studies are required to
provide evidence to this. Our results show that loss of PRMT8
results in a decrease in the level of Gfra2 and increase in the
level of Cxcr4, Dhfr, and Efemp1 in single and double knock-
down cells as well. These are established markers of
astrocyte-derived glioma [52, 67, 68]. Furthermore, a recent
genome-wide linkage study of glioma families linked a
PRMT8-related SNP to gliomagenesis [54]. Downstream effect
of this SNP has not been linked to the expression of PRMT8
yet. Although further work is required, these results already
provide strong support to the notion that PRMT8 might be a
genetic risk factor in gliomagenesis and also a putative thera-
peutic target. Regardless of the mechanism, our results impli-
cate PRMT8 as a biomarker of glioma tissues.
CONCLUSIONS
In summary, the results of this study suggest a novel and so
far unprecedented mechanism of how two evolutionary linked
proteins with similar enzymatic activity can have distinct
effects on cellular differentiation through the integration of
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retinoid signaling acting as parts of a rheostat. These results
provide a new conceptual framework for the interpretation of
retinoid signaling in neuronal differentiation and potentially in
other tissues as well. These proteins, PRMT1 and PRMT8, can
also be targeted pharmacologically to modulate neuronal dif-
ferentiation in vitro or in vivo and might also be a relevant
target in a major unresolved clinical issues such as gliomas
and Alzheimer’s disease.
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